Related Experiment Videos
Acute lymphoblastic leukemia in adults.
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.
Current Treatment Options in Oncology
|June 12, 2002
Summary
Adult acute lymphoblastic leukemia (ALL) therapy faces challenges due to age and risk factors, despite intensive chemotherapy and CNS prophylaxis. Allogeneic bone marrow transplant improves outcomes for high-risk patients, while further research is ongoing.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Adult acute lymphoblastic leukemia (ALL) treatment outcomes lag behind pediatric cases.
- Older age and adverse risk factors complicate adult ALL therapy.
- Current ALL treatment involves intensive chemotherapy, CNS prophylaxis, and maintenance therapy.
Purpose of the Study:
- To review the current therapeutic landscape for adult ALL.
- To compare treatment outcomes between adult and pediatric ALL.
- To discuss the role of stem cell transplantation in adult ALL management.
Main Methods:
- Review of established chemotherapy regimens for ALL.
- Analysis of outcomes for intensive chemotherapy and CNS prophylaxis.
- Evaluation of allogeneic and autologous blood and marrow transplant (BMT) efficacy.
Main Results:
- Complete remission rates in adults are lower than in children, with frequent relapses.
- Allogeneic BMT improves outcomes for high-risk adult ALL patients.
- The efficacy of autologous transplantation and allogeneic transplant in standard-risk patients requires further investigation.
Conclusions:
- Adult ALL therapy requires tailored approaches due to age and risk factors.
- Allogeneic BMT is a viable option for high-risk adult ALL.
- Ongoing research and new agents offer hope for improved cure rates in adult ALL.